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Abstract 
Background: In the Republic of Congo, previous epidemiological studies have only been conducted in the south 
of the country where it is most accessible. Nationally representative data on the efficacy of new anti‑malarial tools 
are lacking in the country. As an initial step to close the gap, clinical efficacy of two artemisinin‑based combinations, 
artesunate‑amodiaquine (ASAQ) and artemether‑lumefantrine (AL), was assessed in Owando, a city in equatorial 
flooded forest in northern Republic of Congo.
Methods: Under 12 years old febrile children attending public health facilities were screened for malaria parasites 
using lactate dehydrogenase (LDH)‑based rapid diagnostic test (RDT) for malaria and microscopic examination of 
thick blood films. Patients with at least 1,000 asexual Plasmodium falciparum parasites/µl of blood were clinically 
examined, included after informed consent, and followed up for 28 days, according to the 2009 World Health Organi‑
zation protocol. Patients were randomly assigned to co‑formulated ASAQ (Coarsucam®) or AL (Coartem®) treatment 
groups. Plasmodium falciparum recrudescent isolates were compared to pre‑treatment isolates by polymerase chain 
reaction (PCR) using msp1, msp2, and glurp genes to distinguish between re‑infection and recrudescence.
Results: Between November 2012 and February 2013, 857 under 12 years old febrile children were screened, of 
whom 198 (23.1 %) had positive RDT and 167 (19.5 %) positive thick films. ASAQ and AL efficacies were 92.7 and 
94.2 % before PCR correction, respectively. After genotyping, the overall efficacy was 100 % for ASAQ and 98.0 % for 
AL.
Conclusion: The data reported here represent partially the burden of malaria in 0–11 years old febrile children 
examined in public health centres of Owando city and serve as reference for further studies. Both artemisinin‑based 
combinations were highly efficacious in patients under 12 years old with acute uncomplicated malaria. ASAQ was 
associated with more adverse events, which may reduce compliance in unsupervised treatment.
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Background
Despite international commitments that have led to 
the global malaria strategy from which the first results 
are expected within the Millennium Development 
Goals in 2015 [1–4], the decline in malaria incidence 
in sub-Saharan African countries may be temporary. In 
2013, it was estimated that 198 million malaria episodes 
occurred, of which 82 % (163 million) were in sub-Saha-
ran African countries. Mortality remained at a high level 
with 584,000 deaths, of which 90 % were reported from 
sub-Saharan African countries [5]. Using malaria control 
tools, mainly long-lasting insecticide-treated nets (ITN), 
intermittent preventive treatment during pregnancy, 
and artemisinin-based combination therapy (ACT), 
some sub-Saharan African countries have registered a 
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substantial reduction in malaria burden in recent years. 
The quality of health systems has also contributed to this 
positive trend. In Central African countries, however, the 
complexity of the ecological context and poorly operating 
health system, including the lack of malaria surveillance 
system, limit the implementation of effective strategy to 
control malaria.
After several decades of intensive use of chloroquine 
and sulfadoxine-pyrimethamine (SP) to treat uncom-
plicated malaria, these two classical anti-malarial drugs 
had become less effective [6–9], resulting in a high per-
centage of malaria cases seen in health centres [10] and 
an increase in the number of severe malaria cases and 
malaria-associated mortality in hospitals [11, 12]. As a 
consequence, in 2006, the Republic of Congo adopted 
ACT as the first-line treatment [13]. Two forms of ACT, 
artesunate-amodiaquine (ASAQ) and artemether-lume-
fantrine (AL), which have become first- and second-line 
anti-malarial treatment, respectively, have proven effec-
tive during the initial clinical assessment [14–16].
To encourage the use of these new treatments by health 
personnel, the Congolese government decreed in 2008 
free malaria treatment for all children less than 15 years 
old. ITNs have also been distributed free of charge to 
pregnant women and children under 5 years of age. This 
mass distribution was later extended to the entire popu-
lation and performed regularly. Pregnant women also 
receive three doses of SP for intermittent preventive 
treatment of malaria. These measures have contributed 
to the reduction of malaria in pregnant women and chil-
dren [17]. However, the available data are still inadequate 
to reflect the evolution of malaria throughout the coun-
try since most previous studies had been conducted in 
southern Republic of Congo.
The present study was conducted to assess the thera-
peutic efficacy of ASAQ and AL from November 2012 
to February 2013 in the city of Owando, located in equa-
torial flooded forest in northern Republic of Congo. All 
febrile children aged less than 12  years spontaneously 
consulting at one of two public health centres were 
screened for the presence of malaria parasites using rapid 
diagnostic test (RDT) and microscopy. The objectives 
of this study were to determine the burden of malaria 
among febrile children less than 12  years old consult-
ing spontaneously at the health centres during the study 
period and to evaluate the tolerance and effectiveness of 
these two forms of ACT.
Methods
Study site
Owando (latitude, 0°28′54″ South; longitude, 15°53′59″ 
East) is the main administrative city of Cuvette Depart-
ment located 550  km to the north of Brazzaville, the 
capital city of the Republic of Congo, and 70 km to the 
south of the Equator, along the Kouyou River, one of the 
tributaries of the Congo River (Fig.  1). The climate is 
sub-equatorial with two rainy seasons, from October to 
December and April to May, and two dry seasons, from 
June to September and January to March. Owando is a 
town in flooded forest and is a strategic choke point for 
northern African countries and migrants from Cam-
eroon and other African countries. Except for a study 
on the in vitro chemosusceptibility of P. falciparum [18], 
there are no existing data on malaria in this part of the 
country. The city has a general hospital, two public health 
centres (No. 1 and No. 2), a military clinic, and private 
health facilities. The present study was conducted in pub-
lic health centres No. 1 and No. 2, which are separated by 
about 2 km.
Malaria diagnosis and inclusion of children under 12 years 
old
Basic clinical information (age, weight, height, axillary 
temperature) of patients from 0 to 11 years was recorded 
in individual clinical forms. In the laboratory, finger-
pick capillary blood was collected for RDT for malaria 
(Advantage Mal Card, J. Mitra & Co. Pvt. Ltd., New 
Delhi, India), preparation of thick films, haematocrit 
measurement, and storage of parasite DNA. Giemsa-
stained thick films were examined under the microscope 
to determine the parasite density. Children with parasite 
density equal to or greater than 1000 asexual parasites/
µl of blood were examined by a medical doctor. Children 
with fever (axillary temperature  ≥37.5  °C), sufficient 
Fig. 1 Map of the Republic of Congo showing the location of 
Owando city
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parasite load (≥1000 P. falciparum asexual parasites/
µl), without any concomitant febrile illness or any signs 
of danger or severe and complicated malaria, were 
included according to the 2009 WHO protocol for the 
assessment of anti-malarial drug efficacy after informed 
consent [19].
Treatment and follow‑up
This was an open-label study. Eligible patients were allo-
cated to one of the two treatment groups after randomi-
zation in blocks of 10 according to a pre-established list 
of treatment groups. Blocks 1, 3, 5, 7, and 9 were affected 
to ASAQ; patients assigned to blocks 2, 4, 6, 8, and 10 
were treated with AL. Patients assigned to AL group 
(20  mg artemether  +  120  mg lumefantrine, Coartem®; 
Novartis, Basel, Switzerland; lot F2545) received 1 tablet 
per dose for 5–14 kg body weight, 2 tablets per dose for 
15–24  kg body weight, 3 tablets per dose for 25–34  kg 
body weight, and 4 tablets per dose for  ≥35  kg body 
weight. Each patient received a total of 6 doses (first dose 
at inclusion on day 0, second dose 8 h after the first dose 
on day 0, then one dose in the morning and another dose 
in the evening on days 1 and 2). Patients treated with 
artesunate-amodiaquine (ASAQ, Coarsucam®, Sanofi-
Aventis, Casablanca, Morocco; lot 5250) received one 
tablet containing 25 mg of AS/67.5 mg of AQ for <9 kg 
body weight, one tablet of 50 mg of AS/135 mg AQ for 
9 to <18 kg, one tablet of 100 mg of AS/270 mg AQ for 
18 to <36  kg, and two tablets of 100  mg of AS/270  mg 
AQ for ≥36 kg of body weight. ASAQ was administered 
once daily for 3 days. Both drugs were provided by Drug 
Resistance and Containment, Global Malaria Programme 
of the World Health Organization (WHO), Geneva, 
Switzerland.
The patients were followed on days 1, 2, 3, 7, 14, 
21, and 28, as in the previous studies on the efficacy of 
ASAQ and AL in the Republic of Congo. Clinical exami-
nation and measurement of axillary temperature were 
performed during each visit, and any adverse events or 
unauthorized concomitant therapies were recorded. As 
recommended in the 2009 WHO protocol [19], blood 
films were examined on days 2, 3, 7, 14, 21, 28, and dur-
ing any unscheduled visit if the patient became febrile. If 
parasites reappeared on or after day 7, fingerprick capil-
lary blood was collected on Whatman® 3MM filter paper 
for polymerase chain reaction (PCR) analysis. The filter 
papers were stored in airtight plastic bags with desiccant 
and stored at room temperature.
DNA extraction and Plasmodium falciparum genotyping
In case of treatment failure, parasites before treat-
ment (day 0 pre-treatment sample) were compared 
to parasites detected on the day of treatment failure. 
Parasite DNA was extracted from filter papers using 
EZNA blood DNA kit (Biofidal, Vaulx-en-Velin, France) 
according to the manufacturer’s recommendations. The 
allelic families and fragment size of merozoite surface 
antigen gene 1 (msa1, NCBI Gene ID: 813575, Plas-
moDBlocus tag: PF3D7_0930300), merozoite surface 
antigen gene 2 (msa2, NCBIGene ID: 812660, PlasmoD-
Blocus tag: PF3D7_0206800), and the fragment size of 
glutamine-rich protein (glurp, NCBIGene ID: 810501, 
PlasmoDBlocus tag: PF3D7_1035300) were compared, as 
recommended by the WHO [20].
Statistical analysis and treatment outcomes
Malaria burden
Clinical data from all enrolled children were entered into 
Excel spreadsheet. The analysis was performed using 
Epi-info 6.04 (Centres for Disease Control and Preven-
tion, Atlanta, GA) to determine the percentage of febrile 
children attending public health facilities with malaria 
parasites detected with either microscopy or RDT. The 
performance of microscopy, as compared to RDT, was 
assessed by calculating the sensitivity (Se), specificity 
(Sp), positive predictive value (PPV), and negative pre-
dictive value (NPV). Cohen’s kappa coefficient (κ) was 
determined to measure the degree of agreement between 
the two diagnostic tests [21]. The 95 % confidence inter-
vals [95  % CI] of the proportions of positive thick films 
and RDT, Se, Sp, PPV, and NPV were determined using 
the exact binomial method.
Sample size determination
The sample size was calculated based on an expected 
failure rate of 5, 10 % precision, and a confidence level of 
95  %, with an estimated loss of 20  % due to exclusions, 
withdrawals, and loss-to-follow-up. At least 60 patients 
per treatment group were recruited [19].
Treatment outcomes
Clinical and parasitological data were analysed using 
the pre-programmed Excel spreadsheet provided by the 
Global Malaria Programme, WHO (Geneva, Switzer-
land). Patients who were excluded or lost to follow-up 
during the 28-day period were excluded from further 
analysis. Per protocol analysis is recommended by the 
WHO protocol and allows comparison of data with those 
of other sentinel sites in the country, mainly Brazzaville. 
Treatment responses were classified before and after 
PCR correction, as described in previous studies [15, 16].
The baseline characteristics of patients were com-
pared using the Student’s t test. The percentage of 
early treatment failure (ETF), late clinical failure 
(LCF), late parasitological failure (LPF), and adequate 
clinical and parasitological response (ACPR) was 
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calculated. Treatment failure rate was defined as the 
number of patients responding with ETF, LCF, or LPF 
divided by the total number of included patients who 
completed the 28-day follow-up. The 95  % CI of the 
outcomes (ETF, LCF, LPF and ACPR) was determined 
using the exact binomial method. Treatment outcomes 
before and after PCR correction were presented on 
Kaplan–Meier survival curves and compared using the 
LogRank test. The percentages of patients responding 
with ACPR and the frequencies of adverse effects asso-
ciated with each ACT were compared using the Fish-
er’s exact test.
Results
Malaria burden in 0–11 years old children
The study was conducted from November 2012 to Feb-
ruary 2013. A total of 857 febrile children aged from 0 
to 11  years were screened for malaria parasites (Fig.  2). 
Among these children, 198 (23.1  %) had positive RDT, 
and 167 (19.5  %) had positive thick blood films (Fig.  3; 
Table  1). Of 198 positive RDT, 167 (84.3  %) were RDT 
positive and microscopy positive, while 31 (15.7  %) had 
negative thick blood films. When compared to micros-
copy results, the sensitivity and specificity of Advantage 
Mal Card® were 100 and 95.5 %, respectively. The kappa 
857 febrile children < 12 years old
198 positive mRDT
167 positive smears
123 positive smears ≥ 1000 Pf asexual 
parasites/µL
61 AL treated62 ASAQ treated





52 PCR corrected :
49 ACRP
3 new infections













Fig. 2 Enrolment and flow diagram. mRDT malaria rapid diagnostic test, Pf P. falciparum, ASAQ artesunate‑amodiaquine, AL artemether‑lumefan‑
trine, Wth withdrawn, LFU lost to follow up, ETF early treatment failure, LCF late clinical failure, LPF late parasitological failure, ACRP adequate clinical 
and parasitological response
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coefficient (κ) was 0.88, i.e. there was an excellent con-
cordance between RDT and microscopy results.
The percentage of malaria cases increased when rain-
fall decreased (Fig.  3). In November 2012 (monthly 
rainfall, 180  mm), when the largest number of febrile 
children were examined in the present study, only 32 of 
359 (8.9 %) thick films and 35 of 359 (9.7 %) RDT were 
positive. In December 2012 (monthly rainfall, 123 mm), 
27 of 152 (17.8 %) thick films and 33 of 152 (21.7 %) RDT 
were positive. High percentage of febrile patients with 
malaria parasites was registered when rainfall decreased 
(monthly rainfall, 111  mm in January 2013 and 57  mm 
in February 2013): in January 2013, 89 of 272 (32.7  %) 
patients with positive microscopy and 104 of 272 (38.2 %) 
positive RDT and in February 2013, 19 of 74 (25.7  %) 
patients with positive microscopy and 26 of 74 (35.1 %) 
patients with positive RDT.
Drug efficacy
Enrolled patients
From November 2012 to January 2013, 123 malaria-
infected symptomatic children were randomly assigned to 
ASAQ (62 children) or AL (61 children) treatment group 
(Fig. 2). The baseline characteristics of both groups were 
comparable, except for age (Table 2). In the AL treatment 
group, there were more children aged less than 5 years.
Among ASAQ-treated children, one child was referred 
to the general hospital for extreme fatigue and was 
excluded on day 1, and six were lost to follow-up: one 
patient on day 14, three patients on day 21, and two 
patients on day 28. On day 1, 2 of these 6 patients lost-to-
follow-up were still febrile, whereas on day 2 and day 3 all 
of them were afebrile. On day 2, 6 of 61 (9.8 %) patients 
treated with ASAQ still presented low parasitaemia. On 
day 3, all patients had negative smears.
In AL-treated group, three patients were excluded after 
enrollment: two patients were not infected with malaria 
parasites on day 0 after controlling their thick films; 1 
patient had repeated vomiting and was unable to swallow 
Fig. 3 Malaria burden among febrile children less than 12 years old consulting at the health centres in Owando (northern Republic of Congo) from 
November 2012 to February 2013. Malaria‑associated febrile cases are expressed as the percentage of Plasmodium falciparum infections confirmed 
by RDT (Positive RDT) and microscopy (Positive thick film) at the bottom of the bar
Table 1 Performance of  rapid diagnostic test for  malaria 
(Advantage Mal Card®) compared to microscopy in health 
facilities in Owando, Republic of Congo
Sensitivity, 100 % (95 % confidence interval [95 % CI] 97.8–100 %); specificity, 
95.5 % (95 % CI 93.7–96.9 %); positive predictive value, 84.3 % (95 % CI 
78.5–89.1 %); negative predictive value, 100 % (95 % CI 99.4–100 %)
RDT rapid diagnostic test
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oral medication on day 1. Six AL-treated patients were 
lost to follow-up. On day 1, 11 of 56 (19.6 %) patients (per 
protocol population) were still febrile. On day 2 and day 
3, all patients were afebrile. On day 2 and day 3, 7 (12.5 %) 
and 1 (1.8  %) patients had positive thick films, respec-
tively. On day 7, all patients had negative microscopy 
results.
Treatment outcomes
Per protocol analysis of the ASAQ treatment group 
showed four cases of treatment failure: 1 of 55 (1.8  %) 
patients presented LCF and 3 (5.5  %), LPF (Table  3). 
Genotyping showed that all four treatment failures were 
due to new infections, and these patients were censured. 
The overall efficacy represented by ACPR rate was 100 %. 
Among 52 eligible AL-treated patients (per protocol pop-
ulation), one (1.9 %) patient hospitalized during the night 
from day 0 to day 1 was considered as ETF; one (1.9 %) 
responded with LCF, and two (3.9 %) with LPF. After PCR 
analysis, the reappearance of parasites in patients with 
LCF and LPF was shown to be due to new infections, and 
these patients were censured. The PCR-corrected ACPR 
Table 2 Baseline characteristics of febrile children with uncomplicated falciparum malaria enrolled in artesunate-amodi-
aquine (ASAQ) and artemether-lumefantrine (AL) groups
There was a significant difference (p = 0.01) in age between the two treatment groups
SD standard deviation, 95 % CI 95 % confidence interval
Characteristics Treatment group
ASAQ AL
No. of included patients 62 61
Age (months), mean ± SD (range) 71.0 ± 31.8 (9–132) 57.3 ± 30.4 (6–132)
<60 months (<5 years): N; % (95 % CI) 19; 30.6 (19.6–43.7) 29; 47.5 (34.6–60.7)
60–132 months (5–11 years): N; % (95 % CI) 43; 69.4 (56.3–80.4) 32; 52.5 (39.3–65.4)
Weight (kg), mean ± SD (range) 19.9 ± 7.8 (9–57) 18.1 ± 7.8 (7–44)
Sex ratio (F/M) 0.94 (30/32) 1.26 (34/27)
Axillary temperature, mean ± SD (range) (°C) 37.9 ± 1.0 (36.0–40.0) 38.0 ± 1.0 (36.0–40.4)
Parasite density (asexual parasites/µL)
 Geometric mean (range) 37,600 (1550–955,000) 34,200 (1000–700,000)
Self‑medication before consultation: N; % (95 % CI) 0; 0 (0–5.8) 3; 4.9 (1.0–13.7)
Haematocrit, mean ± SD (%) 32.9 ± 5.0 31.9 ± 5.4
Table 3 Artesunate–amodiaquine and artemether-lumefantrine efficacy on day 28 in Owando, Republic of Congo
PCR polymerase chain reaction, 95 % CI 95 % confidence interval, ETF early treatment failure, LCF late clinical failure, LPF late parasitological failure, ACPR 
adequate clinical and parasitological response, * n/N number of new infections divided by number of samples analysed by PCR
ASAQ AL
No. of included patients (intention‑to‑treat) 62 61
PCR‑uncorrected responses on day 28
 Withdrawn or lost to follow up: N; % (95 % CI) 7; 11.3 (4.7–21.9) 9; 14.8 (7.0–26.2)
 Per protocol population: N; % (95 % CI) 55; 88.7 (78.1–95.3) 52; 85.2 (73.8–93.0)
 Failures: N; % (95 % CI) 4; 7.3 (2.0–17.6) 4; 7.7 (2.1–18.5)
 ETF: N; % (95 % CI) 0; 0 (0–5.8) 1; 1.9 (0–10.3)
 LCF: N; % (95 % CI) 1; 1.8 (0–9.7) 1; 1.9 (0–10.3)
 LPF : N; % (95 % CI) 3; 5.5 (1.1–15.1) 2; 3.8 (0.5–13.2)
 ACPR: N; % (95 % CI) 51; 92.7 (82.4–98.0) 48; 92.3 (81.5–97.9)
PCR‑corrected responses on day 28
 Withdrawn + lost‑to‑follow‑up + censured due to new infections: N; % (95 % CI) 11; 17.7 (9.2–29.5) 12; 19.7 (10.6–31.8)
 Per protocol population: N; % (95 % CI) 51; 82.3 (70.5–90.8) 49; 80.3 (68.2–89.4)
 ETF: N; % (95 % CI) 0; 0 (0–7.0) 1; 2.0 (0.1–10.9)
 Recrudescence: N; % (95 % CI) 0; 0 (0–7.0) 0; 0 (0–7.2)
 ACPR: N; % (95 % CI) 51; 100 (93.0–100) 48; 98.0 (89.1–99.9)
 New infections: n/N (%) 4/4 (100) 3/3 (100)
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rate of AL was 98.0  %. The PCR corrected data of both 
treatments in the per-protocol analysis showed no sig-
nificant difference in efficacy (p = 0.5). LogRank survival 
analysis of Kaplan–Meier curves did not show any statis-
tically significant difference (P  >  0.05) between the effi-
cacy of ASAQ and AL before and after PCR correction 
(Figs. 4, 5).
Clinical adverse events
ASAQ treatment was associated with asthenia, vomiting, 
pruritus, abdominal pain, and headache in a few patients, 
whereas few AL-treated children reported asthenia and 
vomiting. These adverse events occurred between day 
1 and day 3 (Table 4). Asthenia was the most frequently 
reported adverse event in both groups, while ASAQ-
treated children had more adverse events than AL-
treated children (p = 0.004).
Discussion
In 2006, the Republic of Congo adopted a new drug 
policy for malaria, which includes the treatment of 
uncomplicated malaria with ASAQ and AL, treat-
ment of severe and complicated malaria with paren-
teral quinine, and recommendations for collective and 
individual preventive measures [13]. Long-lasting insec-
ticide-treated nets (ITN) to protect pregnant women 
and children under 5  years old and intermittent pre-
ventive treatment during pregnancy (IPTp) with SP are 
the key measures of malaria prevention. The efficacy of 
ASAQ and AL had been assessed earlier in two sites, the 
rural Department of Pool and Brazzaville when the new 
anti-malarial drug policy was in preparation [14–16]. A 
longitudinal survey in urban and suburban health facili-
ties in Brazzaville, the capital city, from 2003 to 2007 
showed high percentage of clinical malaria episodes 
[10]. In 2011 and 2012, a study conducted among chil-
dren under 5 years old and pregnant women in Brazza-
ville and Pointe-Noire (western Congo along the Atlantic 
coast) reported a reduction of malaria prevalence due 
to preventive measures [16]. This reduction in malaria 
burden could have been even greater if treatment for 
malaria had been provided free of charge to all malaria-
infected patients in public health facilities since 2007, as 
initially planned by the government. Unfortunately, the 
limited supply of ACT in health centres and the high 
price of these drugs in pharmacies have limited the suc-
cess of the measures [22].
RDTs are important tools that contribute to fight effec-
tively against malaria. The ease of use of these devices 
allows untrained medical personnel to use them after a 
short training. Despite many advantages, the use of RDTs 
in Congolese health facilities is limited by its high cost 
and/or lack of adequate supply to meet the country’s 
demands. In public health centres with a microscope, the 
performance of microscopy to establish malaria diagno-
sis costs 500 FCFA (US $1.00). The local laboratory sup-
pliers sell a box containing 25 RDTs for 25,000 FCFA, i.e. 
US $2.00 per RDT. At this price, RDT is not competitive 
in public health facilities.
In Uganda, the treatment of clinical malaria epi-
sodes was cost-effective when diagnosis was established 
with RDT, as compared to microscopic examination of 
thick blood films [23], while in Tanzania the benefit of 
RDT was observed in moderate and low transmission 
areas [24]. In Ghana, a reduction in treatment cost was 
obtained with RDT, as compared with presumptive treat-
ment, but RDT was not advantageous when compared to 
microscopic diagnosis [25]. Several studies have shown 
that anti-malarial treatment is more cost-effective when 
diagnosis is confirmed with RDT, as compared to treat-
ment based on presumptive diagnosis [26]. Although 
Global Fund provides funding to recipient countries to 
acquire RDT [27], the impact of this programme is not 
yet known. In several research studies conducted in 
sub-Saharan Africa, RDTs have been acquired as part 
of research projects funded by donors or as a donation 
[23–25, 28–31]. In African private hospitals, several 













Fig. 4 Kaplan–Meier survival analysis of PCR‑uncorrected outcomes 
of ASAQ (black squares) and AL (black circles) treatment













Fig. 5 Kaplan–Meier survival analysis of PCR‑corrected outcomes of 
ASAQ (white diamonds) and AL (white triangles) treatment
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trademarks of RDT are used without taking into account 
the evaluation of RDT performed by the WHO [32–34].
Under these conditions, microscopy is expected to 
continue to occupy an important place in the diagnosis 
of malaria in the context of declining malaria prevalence, 
with a decrease in the number of clinical malaria cases, 
and for determining parasite density, when required, 
as long as RDT is not subsidized like drugs. Whether 
malaria diagnosis is confirmed by microscopy or RDT, a 
strong commitment of sub-Saharan African states would 
be essential to implement the national and regional anti-
malarial treatment guidelines [35].
This is the first epidemiological study conducted on 
malaria in the northern part of the country reporting 
malaria percentage in 0–11  years old febrile children 
attending health facilities spontaneously and drug effi-
cacy. A reliable diagnosis was established in individual 
patients using both microscopy and RDT. Advantage Mal 
Card® RDT is known for its good performance [33, 34], 
and it is the second time that this device was used in an 
epidemiological study in the Republic of Congo [17]. The 
combination of these two diagnostic methods ensures 
that these data can serve as a reference for future studies 
in the city of Owando.
The choice of age group 0–11 years constitutes one of 
the weaknesses of this study. An enrollment of all symp-
tomatic malaria-infected patients (children and adults) 
would have generated more representative data in the 
health centres. The choice of 0–11  years old is justified 
by a limited quantity of available RDT. However, the 
0–11 years age group is pertinent and of interest because 
it includes children under 5 years old who are considered 
as one of the target age groups, together with pregnant 
women, in the fight against malaria. The longitudinal 
study in Brazzaville from 2003 to 2007 (i.e. before the 
new anti-malarial drug policy based on ACT) had shown 
that in a suburban area of Brazzaville, 46.6  % of febrile 
children under 5 years old and 63.5 % of febrile patients 
aged between 5 and 10 years had clinical malaria [10]. By 
contrast, in the urban area of Brazzaville, 24 % of febrile 
patients under 5  years old and 33.5  % of patients aged 
between 5 and 10  years had malaria [10]. Studies con-
ducted in Mayombe forest in southern Congo, where the 
annual entomological inoculation rate is high but vari-
able (80–400 infective bites/man/year) [36], showed the 
frequency of malaria-associated clinical episodes of 35.4, 
32.1, and 33.3  % in febrile children aged between 0 to 
<2 years, 2 to <5 years and 6–15 years, respectively [37]. 
This latter study also reported that malaria was the third 
cause of consultation in under 2  years old children and 
the fourth cause among children aged 2–15  years, after 
respiratory and gastro-intestinal diseases. With the low 
percentage of clinical malaria episodes among febrile 
children attending public health facilities in Owando city, 
it is likely that the majority of 0–11  years old patients 
consult for febrile diseases other than malaria as in 
Mayombe forest, including acute respiratory infections, 
upper respiratory tract infections, and gastro-intestinal 
infections.
Despite the unavailability of inoculation rate data, the 
city of Owando, located in a forest with shallows that are 
often flooded and scattered dwellings, may be considered 
as an area of high transmission encountered in Congolese 
forest regions. However, based on the results of the pre-
sent study, the percentage of malaria-associated clinical 
episodes (i.e., 19.5 %) among patients 0–11 years attend-
ing Owando health centres appeared to be unusually low. 
Further studies at different times of the year are required 
to characterize malaria transmission in Owando.
In therapeutic efficacy studies, RDT which detects P. 
falciparum lactate dehydrogenase (PfLDH) can be used 
for rapid screening of patients for inclusion, and para-
site density can be determined by microscopy [28]. In 
the present study, RDT was used to screen patients for 
Table 4 Adverse events associated with  artesunate-amodiaquine (ASAQ) and  artemether-lumefantrine (AL) treatment 
in Owando health facilities
N number of patients followed up, n number of patients with adverse events
a There were no reported adverse events on day 3 in the AL group
† There was a statistically significant difference (p = 0.004) in the proportions of ASAQ- and AL-treated patients reporting adverse events
Adverse events ASAQ (n/N; %) AL (n/N; %)a
Day 1 Day 2 Day 3 Total Day 1 Day 2 Total
Asthenia 4/61; 5.6 6/61; 9.8 3/59; 5.1 13/181; 7.2 1/57; 1.8 1/56; 1.8 2/113; 1.8
Vomiting 3/61; 4.9 0/61; 0 0/59; 0 3/181; 1.6 1/57; 1.8 0/56; 0 1/113; 0.9
Headache 0/61; 0 1/61; 1.6 0/59; 0 1/181; 0.6 0/57; 0 0/56; 0 0/113; 0
Urticaria 0/61; 0 1/61; 1.6 0/59; 0 1/181; 0.6 0/57; 0 0/56; 0 0/113; 0
Abdominal pain 1/61; 1.6 1/61; 1.6 1/59; 1.7 3/181; 1.7 0/57; 0 0/56; 0 0/113; 0
Total 8/61; 13.1 9/61; 14.8 4/59; 6.8 21/181; 11.6† 2/57; 0.7 1/56; 0.4 3/113: 2.7†
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inclusion in the study of ASAQ and AL efficacy. The 
PCR-corrected efficacy in Owando city was 100  % for 
ASAQ and 98.0 % for AL, which is in agreement with the 
results obtained in an earlier study conducted in a rural 
area in the Department of Pool, 200 km from Brazzaville, 
where the efficacy rate was 98.5 % for ASAQ (non-cofor-
mulated tablets) and 100  % for AL [13]. These ASAQ 
and AL drug formulations had 94.4 and 97.1 % efficacy, 
respectively, in previous studies in Brazzaville [15, 16]. 
Adverse events related to ASAQ intake and reported in 
studies in Congo [14–16] may become one of the causes 
of non-compliance among patients or their parents for 
this drug provided free of charge in public health facili-
ties. AL is generally better accepted by the population, 
which has led the Congolese health authorities to recom-
mend this ACT as the first-line drug and ASAQ as the 
second-line drug since 2014 [38]. However, AL requires 
six doses to cure malaria, and it is recommended to take 
AL with fatty food or drink. There are at present on the 
Congolese market more than a dozen AL specialties. Sev-
eral dispersible formulations for children, with a fruity 
taste facilitating administration to children, are also 
available. The abundance of AL specialties available and 
freely prescribed in health facilities increases the risk of 
dissemination of poor quality drugs.
Conclusion
This is the first study that provides data on clinical 
malaria episodes in patients aged between 0 and 11 years 
attending public health facilities in Owando, located in 
northern Republic of Congo, and clinical efficacy of two 
ACT (ASAQ and AL) for the treatment of uncomplicated 
falciparum malaria. Data presented here show a relatively 
low proportion of clinical episodes of malaria among 
febrile children attending public health facilities and high 
efficiency of both ACT recommended by the Congo-
lese National Malaria Control Unit for the treatment of 
laboratory-confirmed uncomplicated malaria in health 
facilities.
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